PMID- 26208279
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20200306
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 7
DP  - 2015
TI  - Immunohistochemistry and Fluorescence In Situ Hybridization Can Inform the 
      Differential Diagnosis of Low-Grade Noninvasive Urothelial Carcinoma with an 
      Inverted Growth Pattern and Inverted Urothelial Papilloma.
PG  - e0133530
LID - 10.1371/journal.pone.0133530 [doi]
LID - e0133530
AB  - Urothelial carcinoma (UC) comprises a heterogeneous group of epithelial neoplasms 
      with diverse biological behaviors and variable clinical outcomes. Distinguishing 
      UC histological subtypes has become increasingly important because prognoses and 
      therapy can dramatically differ among subtypes. In clinical work, overlapping 
      morphological findings between low-grade noninvasive UC (LGNUC), which exhibits 
      an inverted growth pattern, and inverted urothelial papilloma (IUP) can make 
      subclassification difficult. We propose a combination of immunohistochemistry 
      (IHC) and molecular cytogenetics for subtyping these clinical entities. In our 
      study, tissue microarray immunohistochemical profiles of Ki-67, p53, cytokeratin 
      20 (CK20) and cyclinD1 were assessed. Molecular genetic alterations such as the 
      gain of chromosomes 3, 7 or 17 or the homozygous loss of 9p21 were also assessed 
      for their usefulness in differentiating these conditions. Based on our analysis, 
      Ki-67 and CK20 may be useful for the differential diagnosis of these two tumor 
      types. Fluorescence in situ hybridization (FISH) can also provide important data 
      in cases in which the malignant nature of an inverted urothelial neoplasm is 
      unclear. LGNUC with an inverted growth pattern that is negative for both Ki-67 
      and CK20 can be positively detected using FISH.
FAU - Sun, Juan-Juan
AU  - Sun JJ
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China; Institute of Pathology, Fudan University, Shanghai, China.
FAU - Wu, Yong
AU  - Wu Y
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China; Institute of Pathology, Fudan University, Shanghai, China.
FAU - Lu, Yong-Ming
AU  - Lu YM
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China.
FAU - Zhang, Hui-Zhi
AU  - Zhang HZ
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China; Institute of Pathology, Fudan University, Shanghai, China.
FAU - Yang, Xiao-Qun
AU  - Yang XQ
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Institute of Pathology, Fudan University, Shanghai, China.
FAU - Sun, Meng-Hong
AU  - Sun MH
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China; Institute of Pathology, Fudan University, Shanghai, China.
FAU - Wang, Chao-Fu
AU  - Wang CF
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China; Institute of Pathology, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20150724
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Carcinoma/*diagnosis/mortality
MH  - Diagnosis, Differential
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Neoplasm Grading
MH  - Papilloma, Inverted/*diagnosis
MH  - Prognosis
MH  - Urologic Neoplasms/*diagnosis/mortality
PMC - PMC4514649
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/07/25 06:00
MHDA- 2016/05/06 06:00
PMCR- 2015/07/24
CRDT- 2015/07/25 06:00
PHST- 2015/01/15 00:00 [received]
PHST- 2015/06/28 00:00 [accepted]
PHST- 2015/07/25 06:00 [entrez]
PHST- 2015/07/25 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
PHST- 2015/07/24 00:00 [pmc-release]
AID - PONE-D-14-58020 [pii]
AID - 10.1371/journal.pone.0133530 [doi]
PST - epublish
SO  - PLoS One. 2015 Jul 24;10(7):e0133530. doi: 10.1371/journal.pone.0133530. 
      eCollection 2015.